Next Science Limited, a medical technology company, develops and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria. The company develops its products using its Xbio Technology platform. It offers SurgX, an innovative surgical gel designed to reduce superficial surgical site infections and protect wound tissue to facilitate natural healing; and Bactisure, a surgical lavage that is used to remove debris, including microorganisms from wounds. The company also provides TorrentX, an antimicrobial wound wash; and BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. In addition, it is developing acne gel; middle ear wash for use in patients with chronic ear infections; minimally invasive surgical lavage to replace a saline wound lavage; nasal packing stent for use in recovery from nasal surgery; adhesion barrier that is implanted in surgery field to prevent internal adhesion; and soft coating for implants. Further, the company develops tropical treatments for school sores, infected atopic dermatitis, and fungal nails; tropical preventative treatment for keloid scarring; and products for bacterial vaginosis, as well as over the counter products, such as mouthwash. Next Science Limited was founded in 2012 and is headquartered in Sydney, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 2 8607 5124
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.46 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Next Science (ASX:NXS) Frequently Asked Questions
What is Next Science's stock symbol?
Next Science trades on the ASX under the ticker symbol "NXS."
Has Next Science been receiving favorable news coverage?
Press coverage about NXS stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Next Science earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Next Science.
Who are some of Next Science's key competitors?
Some companies that are related to Next Science include Aphria (APHA), Knight Therapeutics (GUD), Ecofibre (EOF), Hexo (HEXO), HEXO (HEXO), OrganiGram (OGI), HLS Therapeutics (HLS), Green Organic Dutchman (TGOD), Supreme Cannabis (FIRE), Benchmark (BMK), Flowr (FLWR), CannTrust (TRST), ICC Labs (ICC), Shield Therapeutics (STX) and Amryt Pharma (AMYT).
Who are Next Science's key executives?
Next Science's management team includes the folowing people:
- Ms. Judith Mitchell M.B.A., MD, CEO & Director
- Dr. Matthew Myntti, Founder & CTO
- Ms. Jacqueline Butler CA (ICAEW), Chief Financial Officer
- Mr. Jon Swanson, Chief Operating Officer
- Mr. Don Ayers, VP of Sales & Marketing
What is Next Science's stock price today?
One share of NXS stock can currently be purchased for approximately A$2.75.
How big of a company is Next Science?
What is Next Science's official website?
How can I contact Next Science?
The company can be reached via phone at 61 2 8607 5124.
MarketBeat Community Rating for Next Science (ASX NXS)
MarketBeat's community ratings are surveys of what our community members think about Next Science and other stocks. Vote "Outperform" if you believe NXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
